你的浏览器似乎禁用了 JavaScript。
您必须在浏览器中启用JavaScript才能使用本网站的功能。

微信关注
申请试用装

主页 /
搜索结果：“EGFR”

“EGFR”的搜索结果

Quick View
PCI-32765 (Ibrutinib)

Catalog No. A11020
Quick View

添加到收藏
Bruton tyrosine kinase 抑制剂

PCI-32765 (Ibrutinib)是Bruton酪氨酸激酶（BTK）的口服生物利用小分子抑制剂，具有潜在的抗肿瘤活性。对Bmx，CSK，FGR，BRK及HCK适度有效，对EGFR，Yes，ErbB2，JAK3等作用效果较弱。了解更多

Product Citations (4)

Bulk Inquiry Free Sample
- Simonowski A, .et al. Differential use of BTK and PLC in FcεRI- and KIT-mediated mast cell activation: A marginal role of BTK upon KIT activation, Biochim Biophys Acta Mol Cell Res, 2019, Dec 11;1867(4):118622 PMID: 31837347
- Carolin N. Zorn, .et al. Stimulus strength determines the BTK-dependence of the SHIP1-deficient phenotype in IgE/antigen-triggered mast cells, Sci Rep, 2018, 8: 15467 PMID: 30341350
- Li T, .et al. Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma, Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
- Brittany M. Duggan, .et al. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia, Sci Rep, 2017, 7: 1578 PMID: 28484277

联系我们

Not your Region? View all Distributors

ADOOQ 产品质量保证

Guaranteed product quality, 365 days Unconditional Return & Replacement

We promise all products to perform as described.